Esperion Therapeutics Inc. (NASDAQ:ESPR) traded down 2.1% on Thursday . The company traded as low as $10.63 and last traded at $10.65, with a volume of 152,444 shares traded. The stock had previously closed at $10.88.

A number of equities research analysts have recently weighed in on the company. Vetr downgraded Esperion Therapeutics from a “strong-buy” rating to a “buy” rating and set a $12.60 target price for the company. in a report on Tuesday. Zacks Investment Research upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday, August 9th. JPMorgan Chase & Co. set a $15.00 price target on Esperion Therapeutics and gave the stock a “hold” rating in a research report on Friday, August 5th. Credit Suisse Group AG restated a “sell” rating and issued a $10.00 price target on shares of Esperion Therapeutics in a research report on Wednesday, July 6th. Finally, WallachBeth Capital cut Esperion Therapeutics from a “buy” rating to a “hold” rating and set a $35.00 price target on the stock. in a research report on Tuesday, July 5th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the stock. Esperion Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $24.40.

The firm’s market cap is $239.71 million. The stock’s 50-day moving average price is $10.98 and its 200-day moving average price is $14.78.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.16. During the same period in the prior year, the company posted ($0.55) earnings per share. On average, equities analysts forecast that Esperion Therapeutics Inc. will post ($3.36) EPS for the current year.

In other news, Director Mark E. Mcgovern purchased 5,000 shares of the company’s stock in a transaction dated Wednesday, July 6th. The shares were purchased at an average price of $10.00 per share, with a total value of $50,000.00. Following the transaction, the director now directly owns 600 shares of the company’s stock, valued at $6,000. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

A hedge fund recently raised its stake in Esperion Therapeutics stock. Schwab Charles Investment Management Inc. boosted its position in shares of Esperion Therapeutics Inc. (NASDAQ:ESPR) by 3.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 45,549 shares of the biopharmaceutical company’s stock after buying an additional 1,413 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.20% of Esperion Therapeutics worth $1,014,000 at the end of the most recent quarter.

Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.